Multiple Myeloma – Current Treatment – Current Treatment: Physician Insights – Multiple Myeloma (US)
Multiple myeloma represents a complex and increasingly competitive hematologic malignancy landscape, with treatment approaches evolving rapidly across lines of therapy. While IMiDs, proteasome inhibitors, and anti-CD38 antibodies have long formed the backbone of care, approvals of BCMA-targeted therapies—including CAR-T cells, bispecific antibodies (teclistamab, elranatamab, linvoseltamab), and antibody-drug conjugates (belantamab mafodotin) are significantly expanding options for both newly diagnosed and relapsed/refractory patients. Key assets from Bristol Myers Squibb, Amgen, GSK, Johnson & Johnson, Pfizer, and Sanofi are driving differentiation and intensifying competition as physicians reassess optimal sequencing strategies. Along with greater use of real-world data, safety considerations, and changing treatment guidelines, these advances are reshaping prescribing patterns and market dynamics. As new study results and upcoming therapies challenge existing standards of care, staying up-to-date is important to understand physician choices, access barriers, and the competitive landscape in multiple myeloma.
Questions Answered
- How are BCMA-targeted therapies reshaping treatment sequencing in multiple myeloma, and which modalities (CAR-T vs. bispecific antibodies) are gaining faster adoption in the treatment of relapsed / refractory multiple myeloma?
- Which are the most common combination strategies in the different lines of therapy?
- What proportion of patients undergo autologous stem cell transplant (ASCT), and how does this process affect treatment choice?
- What are the key drivers and main obstacles influencing current prescribing patterns (CAR-Ts, BiTEs) in multiple myeloma?
Product Description
Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
- Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
- Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.
Markets covered: United States.
Primary research: Survey of 100 hematologist-oncologists in the United States fielded in February 2026.
Key drugs covered: Abecma, Carvykti, Darzalex, Kyprolis, Pomalyst, Revlimid, Sarclisa, Tecvayli, Velcade, Xpovio.
